Navigation Links
ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
Date:2/25/2008

Preclinical results to be presented at two international scientific

meetings

ZURICH, Switzerland, Feb. 25 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that it has achieved high concentrations of its antibody fragments in all segments of the eye with topical delivery via eye drops. These data were confirmed in several independent preclinical in vivo tests. Anticipated therapeutic concentrations of ESBATech's antibody fragments were observed in the anterior chamber (front of the eye) and in the posterior segments (back of the eye) including vitreous humour, retina, and choroid. ESBATech's lead antibody fragment ESBA105 is a TNFa antagonist that is scheduled to enter clinical development later in 2008.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080225/NEM037 )

ESBATech also announced today that it will present its preclinical eye penetration data at two upcoming scientific conferences. Dominik Escher, Ph.D., ESBATech's Chief Executive Officer will present at Antibody Engineering Asia in Singapore on February 26, 2008. David Urech, Ph.D., Head of Research & Development at ESBATech will present at the ISOPT 2008 (International Symposium on Ocular Pharmacology and Therapeutics) in Budapest on February 29, 2008.

Dr. Urech commented, "ESBATech's proprietary, repeatable screening platform was employed and generated multiple promising antibody fragment product candidates against several targets for topical ophthalmic use. Antibody fragments have a number of advantages over whole antibodies, resulting from their smaller molecular size. The primary advantage of human antibody fragment is their ability to penetrate tissues much better than whole antibodies. We believe that with our highly stable and monomeric single-chain antibody fragments, we now meet the protein requirem
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
2. Vaccinex Antibody Licensed to GlaxoSmithKline
3. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
4. Human Genome Sciences and Xencor Announce Antibody Collaboration
5. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
6. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
7. Roche Files IND for Second Genmab Antibody
8. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
9. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
10. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
11. Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 BioMedomics, Inc. ... ultra-sensitive POC diagnostic platforms and novel disease specific POC tests, ... of financing netting a total of $690,000. The investment is ... in the company. This group of private investors has significant ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... naturally occurring antibodies contained in, GAMMAGARD LIQUID ... disease, CHICAGO, April 15 The University ... (NYSE: BAX ) today,announced data from a ... [Immune Globulin Intravenous (Human)] (IGIV),marketed as KIOVIG in ...
... BIRMINGHAM, Ala., and CEDARHURST, N.Y., April 15 ,BioHorizons, ... of Implant Logic Systems, Ltd. ("ILS"), first announced ... as a subsidiary of,BioHorizons. Steve Boggan, CEO of ... offering to include VIP Virtual Implant Placement,planning software ...
... PALO ALTO, Calif., April 15 CV Therapeutics,Inc. ... Capital has agreed to pay,CV Therapeutics up to ... percent of,CV Therapeutics, royalty on North American sales ... on closing,of the transaction and could receive a ...
Cached Biology Technology:Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5BioHorizons Announces the Purchase of Implant Logic Systems 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 3
(Date:7/9/2014)... which animals can be found, concern mounts over the ... range for a host mean new territory for its ... of UC Santa Barbara scientists, including parasitologists Ryan Hechinger ... Journal of Biogeography , Hechinger, Kuris and colleagues ... Hosts may actually lose their parasites when the hosts ...
(Date:7/9/2014)... derived from the oils produced by algae may offer ... this goal, optimization of cost effective strategies for large-scale ... needed. Sapphire Energy has developed an innovative solution to ... systems, described in Industrial Biotechnology , a peer-reviewed ... is available on the Industrial Biotechnology ...
(Date:7/9/2014)... Ill. With over 100 diseases that can attack ... top of the most wanted list? University of Illinois ... that more research is needed on the fungus that ... with cool, damp growing conditions but Macrophomina phaseolina ... and dry drought conditions. , "As the climate continues ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4Controlling contamination in open algae ponds for biofuels 2Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... The University of Nottingham are to receive more than 5 ... make rural living in both the UK and India more ... opportunities for small scale energy generation through renewable sources, developing ... of mobile technologies to grow wealth in rural communities. , ...
... landscapes have undergone great change in recent decades, but species ... roe deer, Spanish ibex, red deer and wild boar. ... the effects of changes in land use on the past, ... last few decades there has been an increase in the ...
... serious gastric disorders including stomach cancer may be a step ... chemist. In the first published study of its kind, ... found a carbohydrate-based antigen caused mice to develop antibodies against ... the first jab at a sugar-based vaccine against Helicobacter ...
Cached Biology News:Nottingham researchers help bridge the urban and rural divide in the UK and India 2Nottingham researchers help bridge the urban and rural divide in the UK and India 3Nottingham researchers help bridge the urban and rural divide in the UK and India 4Changes in land use favor the expansion of wild ungulates 2
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... antibody raised against a partial ... Immunogen: TOPORS (NP_005793, 98 ... recombinant protein with GST tag. ... NM_005802 ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
Biology Products: